$599

Kalohexis Files for US IPO

Kalohexis announced it has submitted a draft S-1 registration statement to the SEC ahead of its planned US IPO. The biotech, spun out of Endevica Bio in March 2026, is developing melanocortin-3 and -4 receptor (MC3R/MC4R) therapies for metabolic disorders, including obesity and cachexia in patients with advanced cancers (view website). Below, FENIX provides highlights and insights regarding Kalohexis’s IPO.

This content is for Read Less members only.
Already a member? Log in here